From: Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial
Response
group
P value
control n = 27
n (%)
intervention n = 25
pCR
8 (29.6%)
8 (32%)
0.853
Breast tissue
14 (51.9%)
12 (48%)
0.781
Lymph nodes
11 (40.7%)
11 (44%)
0.812